- Home
- ZNTL vs RANG Comparison
ZNTL vs RANG Comparison
Compare ZNTL & RANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- RANG
- Stock Information
- Founded
- ZNTL 2014
- RANG 2024
- Country
- ZNTL United States
- RANG United States
- Employees
- ZNTL N/A
- RANG N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- RANG
- Sector
- ZNTL Health Care
- RANG
- Exchange
- ZNTL Nasdaq
- RANG Nasdaq
- Market Cap
- ZNTL 137.9M
- RANG 161.0M
- IPO Year
- ZNTL 2020
- RANG 2024
- Fundamental
- Price
- ZNTL $1.29
- RANG N/A
- Analyst Decision
- ZNTL Buy
- RANG
- Analyst Count
- ZNTL 8
- RANG 0
- Target Price
- ZNTL $8.53
- RANG N/A
- AVG Volume (30 Days)
- ZNTL 927.8K
- RANG 8.1K
- Earning Date
- ZNTL 05-06-2025
- RANG 01-01-0001
- Dividend Yield
- ZNTL N/A
- RANG N/A
- EPS Growth
- ZNTL N/A
- RANG N/A
- EPS
- ZNTL N/A
- RANG N/A
- Revenue
- ZNTL $67,425,000.00
- RANG N/A
- Revenue This Year
- ZNTL N/A
- RANG N/A
- Revenue Next Year
- ZNTL N/A
- RANG N/A
- P/E Ratio
- ZNTL N/A
- RANG N/A
- Revenue Growth
- ZNTL N/A
- RANG N/A
- 52 Week Low
- ZNTL $1.01
- RANG $9.91
- 52 Week High
- ZNTL $13.46
- RANG $10.64
- Technical
- Relative Strength Index (RSI)
- ZNTL 39.50
- RANG N/A
- Support Level
- ZNTL $1.01
- RANG N/A
- Resistance Level
- ZNTL $1.32
- RANG N/A
- Average True Range (ATR)
- ZNTL 0.14
- RANG 0.00
- MACD
- ZNTL 0.02
- RANG 0.00
- Stochastic Oscillator
- ZNTL 37.33
- RANG 0.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About RANG Range Capital Acquisition Corp. Ordinary Shares
Range Capital Acquisition Corp is a blank check company.